2013 ASCO Annual Meeting Highlights: May 15, 2013 Webcast with ASCO Chief Medical Officer, Richard Schilsky, MD, FACP, FASCO and ASCO Cancer Communications Committee Chair-Elect, Jyoti Patel, MD

Last Updated: January 21, 2014

A recording of the May 15, 2013 webcast on seven noteworthy studies that will be presented at the upcoming 2013 ASCO Annual Meeting, including:

  • Findings from a 20-year follow-up study of over 17,000 men to assess the impact of cardiorespiratory fitness in middle age on cancer incidence and mortality later in life
  • A phase I study exploring the activity of the anti-PD-L1 antibody MPDL3280A in patients with locally advanced or metastatic solid tumors
  • Results of a phase I study evaluating the combined effect of two immunotherapies – the anti-PD-1 antibody nivolumab and ipilimumab in patients with advanced melanoma
  • Findings from a phase III trial comparing standard-dose and high-dose radiation therapy in patients with advanced non-small cell lung cancer undergoing chemotherapy
  • Results of the largest long-term study to date exploring whether surveillance alone is sufficient for men in remission for stage I seminoma, a common form of testicular cancer
  • A large study examining the use of surveillance imaging scans to detect relapses in patients with diffuse large B cell lymphoma (DLBCL)
  • Final results from a phase I study evaluating idelalisib (GS-1101), a first-in-class PI3Kδ inhibitor, for patients with relapsed or treatment-resistant chronic lymphocytic leukemia

For these studies and more, please visit abstract.asco.org, where the majority of the ASCO Annual Meeting abstracts were released on May 15, 2013. Full-text versions of Plenary, Late-Breaking, and Clinical Review Abstracts will be publically released during the ASCO Annual Meeting, on the scheduled day of their presentation.